The highest level of evidence available as to choice of drug is provided by Goldstein and collaborators [16] who reanalysed an international randomized clinical 6-week trial (RCT) comparing the efficacy of olanzapine (weight gaining) and haloperidol (prolactin raising) to test gender differences in schizophrenia treatment response [14]. Here, PRL is linked to schizophrenia.